Eddy Pharmaceutical announced on October 16 that in order to effectively integrate the company's resources, reduce management costs, and concentrate resources for the company's main business, the company's board of directors reviewed and passed the relevant bill and agreed to cancel the wholly-owned subsidiary Nanjing Ancelai Pharmaceutical Technology Co., Ltd. This cancellation does not involve related transactions, nor does it constitute a major asset restructuring, and there is no need to submit it to the company's shareholders' meeting for consideration.

Eddy Pharmaceutical announced on October 16 that in order to effectively integrate the company's resources, reduce management costs, and concentrate resources for the company's main business, the company's board of directors reviewed and passed the relevant bill and agreed to cancel the wholly-owned subsidiary Nanjing Ancelai Pharmaceutical Technology Co., Ltd. This cancellation does not involve related transactions, nor does it constitute a major asset restructuring, and there is no need to submit it to the company's shareholders' meeting for consideration.